The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics

  title={The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics},
  author={L. Luzzatto},
  journal={The Lancet},
  • L. Luzzatto
  • Published 2010
  • Medicine
  • The Lancet
  • 1their low availability and high cost have greatly delayed large-scale use. In the meantime, a logical alternative was to experiment with existing agents, and there was added pressure to do so because of the increasing frequency of resistance to sulfadoxine-pyrimethamine (Fansidar, Roche, Basel, Switzerland), which was the main alternative to chloroquine. Therefore, in the late 1990s, a combination of chlorproguanil (Lapudrine) and dapsone—both lowcost drugs—known as Lapdap (GlaxoSmithKline… CONTINUE READING
    58 Citations

    Topics from this paper.

    Expanding the Antimalarial Drug Arsenal—Now, But How?
    • 55
    • PDF
    The pharmacogenetics of antimalaria artemisinin combination therapy
    • 31
    Antimalarial Drug Resistance: In the Past, Current Status and Future Perspectives
    • 10
    • PDF
    G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications
    • 124
    • PDF
    A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications
    • H. Elewa, K. Wilby
    • Biology, Medicine
    • European Journal of Drug Metabolism and Pharmacokinetics
    • 2016
    • 12
    Primaquine-induced haemolysis in females heterozygous for G6PD deficiency
    • 22


    Chlorproguanil‐dapsone (LAPDAP) for uncomplicated falciparum malaria
    • P. Winstanley
    • Medicine
    • Tropical medicine & international health : TM & IH
    • 2001
    • 51
    Chlorproguanil-dapsone for treating uncomplicated malaria.
    • 27
    • PDF